Resource Hub

Topic : Type : Press Release

Johnson & Johnson MedTech announces strategic agreement to drive forward innovation for city of Leeds, UK

Johnson & Johnson MedTech UK and Leeds Teaching Hospitals NHS Trust and have revealed a new strategic collaboration to drive forward health innovation plans in West Yorkshire.

The strategic agreement brings together the Trust’s clinical and health innovation expertise with J&J’s innovation capabilities. The partnership will drive lasting improvements to health outcomes in Leeds and across the region and prioritise a focus on addressing health inequalities.

During an event at the Palace of Westminster yesterday (21st November) to update Ministers and partners on progress to build a new hospital on the site of Leeds General Infirmary as part of the Government’s New Hospital Programme, the Chair and Chief Executive of the Trust, Dame Linda Pollard, and Professor Phil Wood, alongside Johnson & Johnson MedTech Managing Director, UK, Hugo Breda; came together to formally announce the organisations had signed a Memorandum of Understanding.

Bringing together NHS and industry expertise to support a thriving health innovation ecosystem in Leeds which will have a local and global impact, this significant agreement will see the organisations collaborate on: 

• Driving forward innovation, R&D and new MedTech for the benefit of all patients, with a focus on improving health equality.
• Promoting skills, talent and jobs in innovation.
• Delivering increased efficiency within the healthcare supply chain, including climate benefits.

Johnson & Johnson MedTech Managing Director, UK, Hugo Breda said ‘This is a significant announcement for health care in Leeds. We believe that through this collaboration we can drive an increase in innovation for unmet healthcare needs, and equality in access to health services for the people of Leeds.

“Our global R&D and manufacturing facility in the city has a significant history in healthcare, being the home of the origins of hip replacement surgery. Today, we have employees working across the spectrum of medical technology development, from 3D printing and robotic surgery to custom medical implant creation and innovative patient education systems. We are excited about utilising this expertise to drive our shared goals with the Leeds Trust.” 

Left - Right:

• Professor Phil Wood, CEO, Leeds Teaching Hospitals NHS Trust
• Dame Linda Pollard
• Hilary Benn, Member of Parliament for Leeds Central
• Hugo Breda, Managing Director, Johnson & Johnson MedTech UK

Ends

About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. For more, visit https://thenext.jnjmedtech.com.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Johnson & Johnson MedTech UK. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Medical Limited and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Johnson & Johnson Medical Limited nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.